Log In
Print
BCIQ
Print
Print this Print this
 

eteplirsen (AVI-4658)

  Manage Alerts
Collapse Summary General Information
Company Sarepta Therapeutics Inc.
DescriptionPhosphorodiamidate morpholino oligomer (PMO) targeting exon 51
Molecular Target DNA
Mechanism of Action 
Therapeutic ModalityNucleic acid: Linear RNA
Latest Stage of DevelopmentPhase III
Standard IndicationMuscular dystrophy
Indication DetailsTreat Duchenne muscular dystrophy (DMD)
Regulatory Designation

U.S. - Fast Track (Treat Duchenne muscular dystrophy (DMD));
U.S. - Orphan Drug (Treat Duchenne muscular dystrophy (DMD));
EU - Orphan Drug (Treat Duchenne muscular dystrophy (DMD))

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today